{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:12Z","timestamp":1786987452516,"version":"build-2736575974"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015654","name":"Nicola Murray Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015654","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105080","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:43:36Z","timestamp":1765266216000},"page":"105080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-9161","authenticated-orcid":false,"given":"Sarah J.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.105080_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/ncb1284","article-title":"Cdc2-cyclin E complexes regulate the G1\/S phase transition","volume":"7","author":"Aleem","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib2","article-title":"AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis","volume":"16","author":"Alum","year":"2025","journal-title":"Discov. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105080_bib4","article-title":"IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification","volume":"40","author":"Au-Yeung","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.2016.160","article-title":"CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis","volume":"30","author":"Ayhan","year":"2017","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ygyno.2018.08.039","article-title":"19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes","volume":"151","author":"Aziz","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105080_bib7","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/sj.onc.1207408","article-title":"Cyclin E deregulation alters the biologic properties of ovarian cancer cells","volume":"23","author":"Bedrosian","year":"2004","journal-title":"Oncogene"},{"issue":"7353","key":"10.1016\/j.critrevonc.2025.105080_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105080_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105080_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41588-018-0165-1","article-title":"Genome doubling shapes the evolution and prognosis of advanced cancers","volume":"50","author":"Bielski","year":"2018","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105080_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/jcp.2004.020347","article-title":"Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome","volume":"58","author":"Bondi","year":"2005","journal-title":"J. Clin. Pathol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105080_bib12","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","article-title":"Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies","volume":"78","author":"Caruso","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cjp2.168","article-title":"Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma","volume":"6","author":"Chan","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105080_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9899","article-title":"A novel landscape of nuclear human CDK2 substrates revealed by in situ phosphorylation","volume":"6","author":"Chi","year":"2020","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105080_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.tcb.2021.05.001","article-title":"Cyclin E in normal physiology and disease states","volume":"31","author":"Chu","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.105080_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","article-title":"Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)","volume":"43","author":"Damian","year":"2025","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105080_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.22918","article-title":"Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma","volume":"110","author":"Davidson","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105080_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/cjp2.219","article-title":"MYC amplifications are common events in childhood osteosarcoma","volume":"7","author":"De Noon","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.critrevonc.2025.105080_bib19","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","author":"Dietrich","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105080_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105080_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015498","article-title":"Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer","volume":"5","author":"Etemadmoghadam","year":"2010","journal-title":"Plos One"},{"key":"10.1016\/j.critrevonc.2025.105080_bib23","article-title":"Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer","volume":"2024","author":"Ewing","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.critrevonc.2025.105080_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.774845","article-title":"Cyclin E\/CDK2: DNA replication, replication stress and genomic instability","volume":"9","author":"Fagundes","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105080_bib25","first-page":"1235","article-title":"Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a gynecologic oncology group study","volume":"63","author":"Farley","year":"2003","journal-title":"Cancer Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.105080_bib26","first-page":"5513","volume":"41","author":"Fu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10_ement","key":"10.1016\/j.critrevonc.2025.105080_bib27","doi-asserted-by":"crossref","first-page":"A006","DOI":"10.1158\/1535-7163.TARG-25-A006","article-title":"Abstract A006: Biomarker analyses of WEE1 inhibition in patients with refractory CCNE1 amplified solid tumors","volume":"24","author":"Fu","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105080_bib28","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter phase II Trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib29","first-page":"242","article-title":"Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer","volume":"60","author":"Fukuse","year":"2000","journal-title":"Cancer Res."},{"issue":"7907","key":"10.1016\/j.critrevonc.2025.105080_bib30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(03)00645-7","article-title":"Cyclin E ablation in the mouse","volume":"114","author":"Geng","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105080_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216057","article-title":"Molecular characteristics and clinical behaviour of epithelial ovarian cancers","volume":"555","author":"Hollis","year":"2023","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105080_bib33","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-22-0368","article-title":"Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification","volume":"28","author":"Hollis","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5797","key":"10.1016\/j.critrevonc.2025.105080_bib34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1126\/science.1130512","article-title":"CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage","volume":"314","author":"Huang","year":"2006","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105080_bib35","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1158\/1078-0432.CCR-16-2217","article-title":"Cytoplasmic cyclin E predicts recurrence in patients with breast cancer","volume":"23","author":"Hunt","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105080_bib36","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1742-1241.2006.01105.x","article-title":"Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1\/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features","volume":"62","author":"Ioachim","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105080_bib37","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8206","article-title":"miR-497\/MIR497HG inhibits glioma cell proliferation by targeting CCNE1 and the miR-588\/TUSC1 axis","volume":"46","author":"Ji","year":"2021","journal-title":"Oncol. Rep."},{"issue":"32","key":"10.1016\/j.critrevonc.2025.105080_bib38","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105080_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/cncr.34582","article-title":"CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an ovarian tumor tissue analysis consortium study","volume":"129","author":"Kang","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105080_bib42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1056\/NEJMoa021153","article-title":"Cyclin E and survival in patients with breast cancer","volume":"347","author":"Keyomarsi","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105080_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152434","article-title":"CCNE1 amplification is associated with liver metastasis in gastric carcinoma","volume":"215","author":"Kim","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"5077","key":"10.1016\/j.critrevonc.2025.105080_bib44","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1126\/science.1388288","article-title":"Formation and activation of a cyclin E-CDK2 complex during the G(1)-phase of the human cell-cycle","volume":"257","author":"Koff","year":"1992","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105080_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-020-00270-2","article-title":"Overexpression of cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors","volume":"9","author":"Kok","year":"2020","journal-title":"Oncogenesis"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecologic Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105080_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10620-008-0464-y","article-title":"Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?","volume":"54","author":"Kouraklis","year":"2009","journal-title":"Digestive Dis. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/path.2005","article-title":"Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression","volume":"209","author":"Koutsami","year":"2006","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A Phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br. J. CANCER"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56674-4","article-title":"Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle","volume":"16","author":"Kumarasamy","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105080_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074060","article-title":"The clinicopathological significance of the Cyclin D1\/E1-cyclin-dependent kinase (CDK2\/4\/6)-retinoblastoma (RB1\/pRB1) pathway in epithelial ovarian cancers","volume":"25","author":"Lashen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6631","key":"10.1016\/j.critrevonc.2025.105080_bib52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/387422a0","article-title":"Myc and Ras collaborate in inducing accumulation of active cyclin E\/Cdk2 and E2F","volume":"387","author":"Leone","year":"1997","journal-title":"Nature"},{"issue":"10271","key":"10.1016\/j.critrevonc.2025.105080_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105080_bib54","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low-molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer","volume":"84","author":"Li","year":"2024","journal-title":"CANCER Res."},{"issue":"50","key":"10.1016\/j.critrevonc.2025.105080_bib55","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1038\/s41388-022-02527-z","article-title":"Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105080_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012860","article-title":"siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model","volume":"5","author":"Liang","year":"2010","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib57","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-020-1580-7","article-title":"Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2","volume":"11","author":"Liang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105080_bib58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jmoldx.2010.11.020","article-title":"Cyclin E1 is amplified and overexpressed in osteosarcoma","volume":"13","author":"Lockwood","year":"2011","journal-title":"J. Mol. Diagnostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2005.06.010","article-title":"A mouse model for cyclin E-dependent genetic instability and tumorigenesis","volume":"8","author":"Loeb","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105080_bib60","first-page":"2470","article-title":"Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development","volume":"59","author":"Lonardo","year":"1999","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24170-0","article-title":"Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets","volume":"12","author":"Lu","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105080_bib62","article-title":"Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1","volume":"83","author":"Ma","year":"2023","journal-title":"Cancer Res."},{"issue":"7694","key":"10.1016\/j.critrevonc.2025.105080_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature25507","article-title":"Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress","volume":"555","author":"Macheret","year":"2018","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105080_bib64","article-title":"CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer","volume":"42","author":"Marra","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2018.06.008","article-title":"The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations","volume":"34","author":"Menghi","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib66","first-page":"11","article-title":"Cyclin E expression, a potential prognostic marker for non-small cell lung cancers","volume":"6","author":"Mishina","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib68","first-page":"647","article-title":"Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer","volume":"61","author":"M\u00fcller-Tidow","year":"2001","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105080_bib69","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cncr.24987","article-title":"Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer","volume":"116","author":"Nakayama","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib70","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3892\/ijo.2015.3268","article-title":"CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas","volume":"48","author":"Nakayama","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib71","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.gastro.2009.05.003","article-title":"Aberrant cell cycle progression and endoreplication in regenerating livers of mice that lack a single E-type Cyclin","volume":"137","author":"Nevzorova","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yexmp.2014.12.004","article-title":"Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes","volume":"98","author":"Noske","year":"2015","journal-title":"Exp. Mol. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105080_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006429","article-title":"Proteomic landscape of tissue-specific cyclin E functions in vivo","volume":"12","author":"Odajima","year":"2016","journal-title":"Plos Genet."},{"key":"10.1016\/j.critrevonc.2025.105080_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109927","article-title":"Ectopic expression of microRNA-874 represses epithelial mesenchymal transition through the NF-kappa B pathway via CCNE1 in cholangiocarcinoma","volume":"82","author":"Pan","year":"2021","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105080_bib75","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0002-9440(10)64592-0","article-title":"High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer","volume":"157","author":"Richter","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105080_bib76","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cncr.21767","article-title":"Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma","volume":"106","author":"Rosen","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105080_bib77","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1158\/2767-9764.CRC-23-0496","article-title":"Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer","volume":"4","author":"Rustgi","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.105080_bib78","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1038\/sj.onc.1210499","article-title":"E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors","volume":"26","author":"Salon","year":"2007","journal-title":"Oncogene"},{"issue":"37","key":"10.1016\/j.critrevonc.2025.105080_bib79","doi-asserted-by":"crossref","first-page":"62240","DOI":"10.18632\/oncotarget.19272","article-title":"CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance","volume":"8","author":"Sapoznik","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105080_bib80","article-title":"Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)","volume":"85","author":"Schram","year":"2025","journal-title":"CANCER Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105080_bib81","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1356","article-title":"Cyclin E overexpression and amplification in human tumours","volume":"200","author":"Schraml","year":"2003","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/cc.11.1.18775","article-title":"An integrated view of cyclin E function and regulation","volume":"11","author":"Siu","year":"2012","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105080_bib83","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1055-9965.EPI-06-0319","article-title":"Cyclin E expression and outcome in pancreatic ductal adenocarcinoma","volume":"15","author":"Skalicky","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"6750","key":"10.1016\/j.critrevonc.2025.105080_bib84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/45836","article-title":"Deregulated cyclin E induces chromosome instability","volume":"401","author":"Spruck","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105080_bib85","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","article-title":"Biomarker assessment of HR deficiency, tumor BRCA1\/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy","volume":"16","author":"Stronach","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105080_bib86","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-17-1240","article-title":"FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1\/CDK2-mediated phosphorylation of CENP-A","volume":"77","author":"Takada","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105080_bib87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbrc.2019.03.009","article-title":"MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer","volume":"512","author":"Tang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105080_bib88","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cub.2015.03.022","article-title":"Cyclin E deregulation promotes loss of specific genomic regions","volume":"25","author":"Teixeira","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/j.critrevonc.2025.105080_bib89","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0959-8049(22)01010-3","article-title":"Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers","volume":"174","author":"Wee","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105080_bib90","article-title":"ACR-2316: A potentially first-in- class, potent, selective WEE1\/PKMYT1 inhibitor rationally designed for superior single agent activity through synergistic disruption of cell cycle checkpoints","volume":"84","author":"Wigerup","year":"2024","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105080_bib91","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4161\/cc.8.7.8119","article-title":"Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression","volume":"8","author":"Wingate","year":"2009","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105080_bib92","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CMR.0000000000000742","article-title":"Clinical significance of CCNE1 copy number gain in acral melanoma patients","volume":"31","author":"Wu","year":"2021","journal-title":"Melanoma Res."},{"key":"10.1016\/j.critrevonc.2025.105080_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09644-6","article-title":"Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer","volume":"10","author":"Xing","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib94","article-title":"Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105080_bib95","article-title":"CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models","volume":"2","author":"Xu","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105080_bib96","article-title":"First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2-breast cancer","volume":"41","author":"Yap","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2025.105080_bib97","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105080_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2023.06.182","article-title":"VELA: A first-in-human phase 1\/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4\/6 inhibitor (CDK4\/6i)-resistant advanced solid tumors","volume":"176","author":"Yap","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2025.105080_bib99","doi-asserted-by":"crossref","first-page":"PR008","DOI":"10.1158\/1535-7163.TARG-23-PR008","article-title":"Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A","volume":"22","author":"Yap","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105080_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110649","article-title":"Circular RNA circSEMA5A facilitates colorectal cancer development by regulating microRNA-195-5p to target CCNE1 axis","volume":"107","author":"Ye","year":"2023","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105080_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.12.036","article-title":"Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication","volume":"186","author":"Zeng","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105080_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104233","article-title":"Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors","volume":"193","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105080_bib103","article-title":"Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.critrevonc.2025.105080_bib104","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5290-4","article-title":"CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105080_bib105","doi-asserted-by":"crossref","DOI":"10.1186\/s41065-023-00273-0","article-title":"CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis","volume":"160","author":"Zheng","year":"2023","journal-title":"Hereditas"},{"key":"10.1016\/j.critrevonc.2025.105080_bib106","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-14-78","article-title":"Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies","volume":"14","author":"Zhou","year":"2014","journal-title":"BMC Gastroenterol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105080_bib107","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ejso.2011.08.139","article-title":"Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer","volume":"37","author":"Zhou","year":"2011","journal-title":"EJSO"},{"issue":"8_Supplement_1","key":"10.1016\/j.critrevonc.2025.105080_bib108","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1158\/1538-7445.AM2025-2909","article-title":"Targeting Pol\u03b8 suppresses CCNE1-amplified cancers via transcription-replication conflicts mediated DNA damage and RAD51 toxicity","volume":"85","author":"Zhu","year":"2025","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:46:29Z","timestamp":1773953189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":108,"alternative-id":["S1040842825004688"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105080","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105080"}}